|
Fludarabine Treatment of Chronic Lymphocytic Leukemia: c-DNA Microarray Gene Expression Analysis, and Pre-Clinical Bone Marrow Transplant/Immunotherapy Studies Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Fludarabine Treatment of Chronic Lymphocytic Leukemia: c-DNA Microarray Gene Expression Analysis, and Pre-Clinical Bone Marrow Transplant/Immunotherapy Studies conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Fludarabine Treatment of Chronic Lymphocytic Leukemia: c-DNA Microarray Gene Expression Analysis, and Pre-Clinical Bone Marrow Transplant/Immunotherapy Studies Clinical research trials and Fludarabine Treatment of Chronic Lymphocytic Leukemia: c-DNA Microarray Gene Expression Analysis, and Pre-Clinical Bone Marrow Transplant/Immunotherapy Studies health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Fludarabine Treatment of Chronic Lymphocytic Leukemia: c-DNA Microarray Gene Expression Analysis, and Pre-Clinical Bone Marrow Transplant/Immunotherapy Studies. Fludarabine Treatment of Chronic Lymphocytic Leukemia: c-DNA Microarray Gene Expression Analysis, and Pre-Clinical Bone Marrow Transplant/Immunotherapy Studies Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Fludarabine Treatment of Chronic Lymphocytic Leukemia: c-DNA Microarray Gene Expression Analysis, and Pre-Clinical Bone Marrow Transplant/Immunotherapy Studies clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Fludarabine Treatment of Chronic Lymphocytic Leukemia: c-DNA Microarray Gene Expression Analysis, and Pre-Clinical Bone Marrow Transplant/Immunotherapy Studies condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "F" Clinical Trials Conditions > Fludarabine Treatment of Chronic Lymphocytic Leukemia: c-DNA Microarray Gene Expression Analysis, and Pre-Clinical Bone Marrow Transplant/Immunotherapy Studies  Fludarabine Treatment of Chronic Lymphocytic Leukemia: c-DNA Microarray Gene Expression Analysis, and Pre-Clinical Bone Marrow Transplant/Immunotherapy Studies
Fludarabine Treatment of Chronic Lymphocytic Leukemia: c-DNA Microarray Gene Expression Analysis, and Pre-Clinical Bone Marrow Transplant/Immunotherapy Studies
For Condition: Chronic Lymphocytic Leukemia
Status: Recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: Fludarabine is the most active agent for the treatment of chronic lymphocytic leukemia (CLL), with up to a 79% response rate in previously untreated patients. However, advanced stage CLL patients treated with fludarabine have only a 33 month disease-free survival; fludarabine does not represent a curative modality for CLL. Because attempts to combine fludarabine with other chemotherapeutic agents have resulted in increased toxicity, single agent fludarabine currently represents the treatment of choice for advanced stage CLL. As such, we have designed this protocol to better understand the genetic basis of CLL, and to develop new transplantation therapies for CLL patients. A new technology utilizing cDNA microarrays now permits the simultaneous quantitation of the expression of thousands of genes; this methodology can evaluate defined cellular pathways, and also discover novel genes influencing cell biology. Using cDNA microarray gene expression analysis on lymphocytes from CLL, we seek to identify genes associated with CLL pathogenesis, and genes associated with either clinical sensitivity or resistance to fludarabine. In addition to improving our understanding of the pathogenesis of CLL, these molecular studies may identify new therapeutic targets in CLL, and may help to identify those CLL patients most likely to respond to fludarabine. This study also focuses on the pre-clinical development of bone marrow transplantation and cellular immunotherapy approaches in fludarabine-treated CLL patients. Allogeneic bone marrow transplantation represents a curative treatment modality in CLL; unfortunately, most CLL patients are not candidates for alloBMT because of increased age and a lack of HLA-matched donors. Because allogeneic donor T cells mediate both the beneficial GVL effect and detrimental graft-versus-host disease (GVHD), prior attempts to separate GVL from GVHD have been largely unsuccessful. Utilizing murine models, we have shown that CD8+ T cells of Tc2 phenotype (cytolytic effectors secreting Type II cytokines) mediated a GVL effect without inducing ongoing GVHD; we have also shown that Tc2 cells prevented graft rejection without inducing GVHD. Allogeneic Tc2 cells may thus represent a population capable of expanding the application of allogeneic immunotherapy in CLL patients. As a step towards clinical translation, we have developed techniques for generating human Tc2 cells. We will now evaluate the generation Tc2 cells in the setting of fludarabine treatment of CLL. In addition, we will further characterize the immunosuppressive effects of fludarabine, and develop CLL purging methodologies which will be needed for future autologous BMT and T cell immunotherapy protocols in CLL.
Details: Fludarabine is the most active agent for the treatment of chronic lymphocytic leukemia (CLL), with up to a 79% response rate in previously untreated patients. However, advanced stage CLL patients treated with fludarabine have only a 33 month disease-free survival; fludarabine does not represent a curative modality for CLL. Because attempts to combine fludarabine with other chemotherapeutic agents have resulted in increased toxicity, single agent fludarabine currently represents the treatment of choice for advanced stage CLL. As such, we have designed this protocol to better understand the genetic basis of CLL, and to develop new transplantation therapies for CLL patients. A new technology utilizing cDNA microarrays now permits the simultaneous quantitation of the expression of thousands of genes; this methodology can evaluate defined cellular pathways, and also discover novel genes influencing cell biology. Using cDNA microarray gene expression analysis on lymphocytes from CLL, we seek to identify genes associated with CLL pathogenesis, and genes associated with either clinical sensitivity or resistance to fludarabine. In addition to improving our understanding of the pathogenesis of CLL, these molecular studies may identify new therapeutic targets in CLL, and may help to identify those CLL patients most likely to respond to fludarabine. This study also focuses on the pre-clinical development of bone marrow transplantation and cellular immunotherapy approaches in fludarabine-treated CLL patients. Allogeneic bone marrow transplantation represents a curative treatment modality in CLL; unfortunately, most CLL patients are not candidates for alloBMT because of increased age and a lack of HLA-matched donors. Because allogeneic donor T cells mediate both the beneficial GVL effect and detrimental graft-versus-host disease (GVHD), prior attempts to separate GVL from GVHD have been largely unsuccessful. Utilizing murine models, we have shown that CD8+ T cells of Tc2 phenotype (cytolytic effectors secreting Type II cytokines) mediated a GVL effect without inducing ongoing GVHD; we have also shown that Tc2 cells prevented graft rejection without inducing GVHD. Allogeneic Tc2 cells may thus represent a population capable of expanding the application of allogeneic immunotherapy in CLL patients. As a step towards clinical translation, we have developed techniques for generating human Tc2 cells. We will now evaluate the generation Tc2 cells in the setting of fludarabine treatment of CLL. In addition, we will further characterize the immunosuppressive effects of fludarabine, and develop CLL purging methodologies which will be needed for future autologous BMT and T cell immunotherapy protocols in CLL.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Low, Intermediate or High-Risk Category of CLL, using the Modified Three-Stage Rai Staging System. Patients in the intermediate risk group should have evidence of active disease as demonstrated by at least one of the following criteria: a) massive or progressive splenomegaly or lymphadenopathy; b) presence of weight loss greater than 10% over the preceding 6 months; c) constitutional symptoms of extreme fatigue, night sweats or recurrent fever of greater than 100 degrees F (documented fevers must be occurring without evidence of specific infection); d) progressive lymphocytosis with an increase of greater than 50% over a 2 month period, or an anticipated doubling time of less than 6 months. Patients with a diagnosis of CLL who do not meet the eligibility criteria for receiving fludarabine (are not intermediate- or high-risk CLL), can enroll on the protocol for the purpose of donating cellular products. Such patients will not receive fludarabine chemotherapy. At a later date, if it is documented that the patient does meet the criteria, then the patient may receive fludarabine (after discussion with the Principal Investigator); in such patients, all of the criteria listed must be met prior to starting fludarabine. In a limited number of cases, patients with low-risk CLL may be initiated on fludarabine treatment. For example, individuals who are candidates for bone marrow transplantation may be started on fludarabine as an induction regimen prior to transplantation. Additionally, some low-risk patients may be started on fludarabine for psychological reasons (patient insistence on starting chemotherapy prior to disease progression). However, it must be stressed that low-risk CLL patients will be discouraged from initiating chemotherapy except in these specific cases. Age greater than or equal to 18 years of age. Patients must have received no prior cytotoxic therapy. ECOG performance status of 0 to 2. Required initial laboratory tests: BUN and Creatinine values must be less than or equal to 1.5 times the normal values; alternatively, patients with creatinine clearance of greater than 50 ml per minute will also be eligible. AST and ALT values must be less than or equal to 2.0 times normal values; patients with laboratory values greater than these levels may be enrolled on the protocol (after a specific approval from the Principal Investigator) if the values are due to a known, pre-existing liver disease. Bilirubin must be less than or equal to 2.0 mg/dl. In addition, patients must be negative for the Direct Coomb's test. The patient must be competent to sign an informed consent, and sign the protocol consent form. EXCLUSION CRITERIA: Patients must not be pregnant or breastfeeding. No patients with active autoimmune hemolytic anemia (AIHA; as indicated by a positive direct Coombs test) or immune thrombocytopenia (ITP) shall be enrolled. Patients with a history of prior steroid therapy to control either AIHA or ITP will be eligible, provided they do not require maintenance corticosteroids, do not have evidence of active autoimmune disease, and have a negative Direct Coomb's Test. Any patient with a medical condition that requires chronic use of corticosteroids shall not be enrolled.
Total Enrollment: 65
Location and Contact Information:
National Cancer Institute (NCI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Clinical Support Center/NCI 1-888-624-1937
Additional Information:
Study ID Numbers: 970178; 97-C-0178
Study Start Date: September 8, 1997
Record last reviewed: August 1, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001586
Other Chronic Lymphocytic Leukemia Studies:
1. Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
2. Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers
3. Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer
4. Phase I Study of BL22, a Recombinant Immunotoxin for Treatment of CD22+ Leukemias and Lymphomas
5. Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia
Related Studies:
Other Chronic Lymphocytic Leukemia Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Fludarabine Treatment of Chronic Lymphocytic Leukemia: c-DNA Microarray Gene Expression Analysis, and Pre-Clinical Bone Marrow Transplant/Immunotherapy Studies
|
|
|
|
|
|
|
|
